CD4 and Kaposi's sarcoma: In summary, whilst we cannot recommend further evaluation of selumetinib 75 mg bd as monotherapy in HIV-associated KS in combination with ART, the clinical benefit rate, improvements in CD4 cell count, and evidence of response in Ang-2 suggest that studies exploring selumetinib in combination with other agents including anti-angiogenic agents and/or immune checkpoint inhibitors are warranted.